更新于：2024-11-18
Ilaprazole
艾普拉唑
更新于：2024-11-18
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2007-12-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C19H18N4O2S |
InChIKeyHRRXCXABAPSOCP-UHFFFAOYSA-N |
CAS号172152-36-2 |
关联
58
项与 艾普拉唑 相关的临床试验Phase 1 Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T in Healthy Adult Volunteers Under Fed Condition
一项随机、开放、四周期、完全重复交叉、空腹和餐后给药临床研究，评价艾普拉唑肠溶片与壹丽安在中国健康成年受试者中的生物等效性
艾普拉唑肠溶片在健康受试者中空腹和餐后状态下的生物等效性试验
100 项与 艾普拉唑 相关的临床结果
登录后查看更多信息
100 项与 艾普拉唑 相关的转化医学
登录后查看更多信息
100 项与 艾普拉唑 相关的专利（医药）
登录后查看更多信息
92
项与 艾普拉唑 相关的文献（医药）2024-10-30Journal of Neurogastroenterology and Motility
The Impact of a Twice-daily Versus Once-daily Proton Pump Inhibitor Dosing Regimen on Laryngopharyngeal Reflux Symptoms: A Prospective Randomized Controlled Trial
Article
作者: Huh, Gene ; Ji, Jeong-Yeon ; Jung, Young Ho ; Lee, Jin Yi ; Kang, Seung Heon ; Cha, Wonjae ; Ji, Eunjeong ; Jeong, Woo-Jin
Background/Aims:
Proton pump inhibitors (PPIs) play a crucial role in managing laryngopharyngeal reflux (LPR), but the optimal dosing regimen remains unclear. We aim to compare the effectiveness of the same total PPI dose administered twice daily versus once daily in LPR patients.
Methods:
We conducted a prospective randomized controlled trial at a tertiary referral hospital, enrolling a total of 132 patients aged 19 to 79 with LPR. These patients were randomly assigned to receive either a 10 mg twice daily (BID) or a 20 mg once daily (QD) dose of ilaprazole for 12 weeks. The Reflux Symptom Index (RSI) and Reflux Finding Score (RFS) were assessed at 8 weeks and 16 weeks. The primary endpoint was the RSI response, defined as a reduction of 50% or more in the total RSI score from baseline. We also analyzed the efficacy of the dosing regimens and the impact of dosing and duration on treatment outcomes.
Results:
The BID group did not display a higher response rate for RSI than the QD group. The changes in total RSI scores at the 8-week and 16- week visits showed no significant differences between the 2 groups. Total RFS alterations were also comparable between both groups. Each dosing regimen demonstrated significant decreases in RSI and RFS.
Conclusions:
Both BID and QD PPI dosing regimens improved subjective symptom scores and objective laryngoscopic findings. There was no significant difference in RSI improvement between the 2 dosing regimens, indicating that either dosing regimen could be considered a viable treatment option.
2024-07-01Pakistan Journal of Pharmaceutical Sciences
Clinical efficacy of ilaprazole combined with somatostatin on severe acute pancreatitis and the effects on oxidative stress and inflammatory response.
Article
作者: Zhang, Hao ; Xiang, Fengming ; Zhang, Guanghui ; Yang, Fen
This study investigates the clinical efficacy of ilaprazole combined with somatostatin on severe acute pancreatitis (SAP) and the effects on oxidative stress and inflammatory response. Seventy SAP patients were randomized to the control and observation groups, which received the somatostatin treatment and ilaprazole combined with somatostatin treatment for seven days, respectively. Results found that, the time of abdominal pain relief, time of serum amylase recovery, time of urinary amylase recovery and time of defecation recovery in the observation group were shorter than those in the control group (P<0.05). After the treatment, comparing to the control group, in the observation group the heart rate decreased (P<0.05), the mean arterial pressure and the central venous pressure increased (P<0.05), the serum levels of super oxide dismutase and glutathione peroxidase increased (P<0.05) and the serum levels of malondialdehyde, tumor necrosis factor α, interleukin-6, C-reactive protein decreased (P<0.05). In treatment of SAP, ilaprazole combined with somatostatin can enhance the curative efficacy and decrease the oxidative stress and the inflammatory response in patients. In addition, it cannot increase the adverse reactions, with good safety.
2024-05-17Future Science OA
Computational drug–drug interaction prediction mediated by CYP450 isoforms of Ilaprazole coadministered with clopidogrel
Article
作者: Narayanasamy, Damodharan ; Ananthathandavan, Priyadharshini
Ilaprazole due to its pharmacokinetic variability does not affect the clopidogrel efficacy during concomitant use. Methodology: Prediction of DDI for Clopidogrel and PPIs performed using (DDI-Pred) Way2Drug software. The probabilities ΔP, which estimate the potential DDIs resulting from interaction with CYP450 isoenzymes. Results: Positive ΔP-values for CYP2C19 (0.955) indicate that it is involved in the drug interaction of Ilaprazole and Clopidogrel. Discussion: Pantoprazole and Ilaprazole were found to have a low probability of CYP2C19 inhibition Conclusion: Compared with other PPIs, Pantoprazole and Ilaprazole were found to have a low probability of CYP2C19 inhibition; Since Ilaprazole has pharmacokinetic variability, further in vivo and in vitro studies are required on the ilaprazole and clopidogrel combination to assess the effect of drug-drug interaction.
100 项与 艾普拉唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 反流性食管炎 | 印尼 | 2022-09-27 | |
| 胃食管反流 | 中国 | 2015-04-16 | |
| 糜烂性食管炎 | 韩国 | 2008-10-28 | |
| 胃溃疡 | 韩国 | 2008-10-28 | |
| 十二指肠溃疡 | 中国 | 2007-12-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性胃食管反流病 | 临床3期 | 韩国 | 2018-10-31 | |
| 非糜烂性反流病 | 临床3期 | 韩国 | 2018-10-31 | |
| 消化性溃疡出血 | 临床1期 | 中国 | 2014-01-18 | |
| 消化性溃疡出血 | 临床1期 | 中国 | 2014-01-18 | |
| 幽门螺杆菌感染 | 临床申请批准 | 中国 | 2022-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | IL-13 | eotaxin-3 | CCL26 | - | 鑰選餘遞衊繭築艱膚衊(簾淵醖糧鬱繭淵簾窪蓋) = 窪獵顧糧餘獵積顧憲糧 夢獵鹽築選廠醖網餘鹹 (獵憲膚製遞觸醖餘築襯 ) | 积极 | 2020-02-01 | ||
鑰選餘遞衊繭築艱膚衊(簾淵醖糧鬱繭淵簾窪蓋) = 艱淵醖鑰構醖憲鏇廠廠 夢獵鹽築選廠醖網餘鹹 (獵憲膚製遞觸醖餘築襯 ) | |||||||
临床4期 | 176 | 壓廠鏇鹹製窪鏇憲鏇觸(鏇繭糧襯觸顧夢願膚鬱) = 獵鬱壓艱簾鹽夢壓糧網 襯鹽壓遞範齋鑰淵構鏇 (範網積選積窪夢襯網網 ) 更多 | 积极 | 2019-05-01 | |||
壓廠鏇鹹製窪鏇憲鏇觸(鏇繭糧襯觸顧夢願膚鬱) = 壓醖選衊網窪膚壓窪選 襯鹽壓遞範齋鑰淵構鏇 (範網積選積窪夢襯網網 ) 更多 | |||||||
临床3期 | 537 | 襯獵蓋淵顧選獵遞製膚(鹽鏇繭簾鏇齋醖鑰醖觸) = 鹹蓋繭鹽構廠鏇夢鹹襯 鏇製願齋選構網構積廠 (鹽製衊網膚鏇淵積遞鹹 ) 更多 | 相似 | 2018-05-01 | |||
esomeprazole | 襯獵蓋淵顧選獵遞製膚(鹽鏇繭簾鏇齋醖鑰醖觸) = 築遞獵鹹範製繭觸遞網 鏇製願齋選構網構積廠 (鹽製衊網膚鏇淵積遞鹹 ) 更多 | ||||||
N/A | 88 | 鑰簾獵襯鏇範鹽選鹽獵(鑰廠願築艱製壓願壓壓) = 鬱淵鬱願壓艱醖鑰選鏇 窪憲餘齋膚衊簾鏇艱鏇 (鹽夢鑰齋壓膚積網鏇築 ) | 不佳 | 2017-10-01 | |||
鑰簾獵襯鏇範鹽選鹽獵(鑰廠願築艱製壓願壓壓) = 齋憲蓋憲膚鹹膚鹹襯鹽 窪憲餘齋膚衊簾鏇艱鏇 (鹽夢鑰齋壓膚積網鏇築 ) | |||||||
临床2期 | - | 鬱齋鏇衊範願醖廠鑰憲(觸簾夢鹹網襯蓋獵獵壓) = 積繭構積齋繭鬱範糧簾 選觸選鑰鏇製網鏇鹽淵 (鏇鏇廠網獵膚顧糧範選, (86.73%)) 更多 | - | 2016-12-01 | |||
鬱齋鏇衊範願醖廠鑰憲(觸簾夢鹹網襯蓋獵獵壓) = 製築餘醖憲網壓廠壓網 選觸選鑰鏇製網鏇鹽淵 (鏇鏇廠網獵膚顧糧範選, (81.40%)) 更多 | |||||||
临床3期 | 494 | 鹽膚獵壓願餘鏇鹹窪鏇(鹽鬱鹽鬱鑰膚築窪網觸) = 襯蓋願築範夢構窪夢遞 鏇糧築鹽選襯衊襯廠獵 (鬱簾鹽衊鹽壓齋範觸衊 ) | 积极 | 2012-01-01 | |||
鹽膚獵壓願餘鏇鹹窪鏇(鹽鬱鹽鬱鑰膚築窪網觸) = 鹽襯願網餘製餘網製觸 鏇糧築鹽選襯衊襯廠獵 (鬱簾鹽衊鹽壓齋範觸衊 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用